Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Non-Current Deferred Tax Liability (2017 - 2018)

Soleno Therapeutics (SLNO) has disclosed Non-Current Deferred Tax Liability for 2 consecutive years, with $1.6 million as the latest value for Q4 2018.

  • For Q4 2018, Non-Current Deferred Tax Liability changed 0.0% year-over-year to $1.6 million; the TTM value through Dec 2018 reached $1.6 million, changed 0.0%, while the annual FY2018 figure was $1.6 million, 0.0% changed from the prior year.
  • Non-Current Deferred Tax Liability hit $1.6 million in Q4 2018 for Soleno Therapeutics, roughly flat from $1.6 million in the prior quarter.
  • Across five years, Non-Current Deferred Tax Liability topped out at $1.6 million in Q4 2017 and bottomed at $1.6 million in Q4 2017.